Ascletis Pharma Statistics
Total Valuation
Ascletis Pharma has a market cap or net worth of 775.01 million. The enterprise value is 510.58 million.
| Market Cap | 775.01M |
| Enterprise Value | 510.58M |
Important Dates
The next estimated earnings date is Friday, May 30, 2025.
| Earnings Date | May 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 962.85M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -6.75% |
| Shares Change (QoQ) | -2.92% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 131.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4,409.10 |
| PB Ratio | 2.88 |
| P/TBV Ratio | 2.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.38 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.84 |
Financial Position
The company has a current ratio of 12.88, with a Debt / Equity ratio of 0.00.
| Current Ratio | 12.88 |
| Quick Ratio | 12.82 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.02 |
| Interest Coverage | -1,658.32 |
Financial Efficiency
Return on equity (ROE) is -13.97% and return on invested capital (ROIC) is -11.70%.
| Return on Equity (ROE) | -13.97% |
| Return on Assets (ROA) | -10.96% |
| Return on Invested Capital (ROIC) | -11.70% |
| Return on Capital Employed (ROCE) | -20.52% |
| Revenue Per Employee | 761 |
| Profits Per Employee | -178,481 |
| Employee Count | 231 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.10 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +319.08% in the last 52 weeks. The beta is 0.33, so Ascletis Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | +319.08% |
| 50-Day Moving Average | 0.42 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 59.81 |
| Average Volume (20 Days) | 7,270 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ascletis Pharma had revenue of 175,775 and -41.23 million in losses. Loss per share was -0.04.
| Revenue | 175,775 |
| Gross Profit | 100,697 |
| Operating Income | -55.44M |
| Pretax Income | -41.23M |
| Net Income | -41.23M |
| EBITDA | -53.49M |
| EBIT | -55.44M |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 267.50 million in cash and 1.05 million in debt, giving a net cash position of 266.46 million.
| Cash & Cash Equivalents | 267.50M |
| Total Debt | 1.05M |
| Net Cash | 266.46M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 269.37M |
| Book Value Per Share | 0.28 |
| Working Capital | 249.03M |
Cash Flow
In the last 12 months, operating cash flow was -46.80 million and capital expenditures -287,022, giving a free cash flow of -47.08 million.
| Operating Cash Flow | -46.80M |
| Capital Expenditures | -287,022 |
| Free Cash Flow | -47.08M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 57.29% |
| Operating Margin | -31,538.05% |
| Pretax Margin | -23,455.66% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Ascletis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 6.75% |
| Shareholder Yield | n/a |
| Earnings Yield | -5.32% |
| FCF Yield | -6.08% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ascletis Pharma has an Altman Z-Score of 4.29.
| Altman Z-Score | 4.29 |
| Piotroski F-Score | n/a |